BioXcel Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

BioXcel Therapeutics

27/03/2025 12:06

BioXcel Therapeutics Inc BTAI.OQ reported a quarterly adjusted loss of $3.57​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of $-12.16.  The mean expectation of six analysts for the quarter was for a loss of $6.42 per share. Wall Street expected results to range from $-12.60 to $-3.68 per share.

Revenue fell 2.7% to $366.00 thousand from a year ago; analysts expected $706.67 thousand.

BioXcel Therapeutics Inc's reported EPS for the quarter was a loss of $3.57​.

The company reported a quarterly loss of $10.86 million.

BioXcel Therapeutics Inc shares had fallen by 63.6% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 10.1% in the last three months.​

In the last 30 days, there have been no negative revisions of earnings estimates

RECOMMENDATIONS

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 3 "hold" and 1 "sell" or "strong sell."

The average consensus recommendation for the pharmaceuticals peer group is also "hold"

Wall Street's median 12-month price target for BioXcel Therapeutics Inc is $16.00

This summary was machine generated from LSEG data March 27 at 12:05 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-6.42
-3.57
Beat
Sep. 30 2024
-8.67
-5.12
Beat
Jun. 30 2024
-11.36
-3.36
Beat
Mar. 31 2024
-11.17
-13.92
Missed